scopolamine transdermal — Competitive Intelligence Brief

scopolamine transdermal (scopolamine transdermal) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic agent. Area: Gastroenterology / Antiemetics.

marketed Anticholinergic agent Muscarinic acetylcholine receptors (M1, M3, M5) Gastroenterology / Antiemetics Small molecule

Target snapshot

scopolamine transdermal (scopolamine transdermal) — Stony Brook University. Scopolamine blocks muscarinic acetylcholine receptors in the central nervous system to prevent nausea and vomiting.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
scopolamine transdermal TARGET	scopolamine transdermal	Stony Brook University	marketed	Anticholinergic agent	Muscarinic acetylcholine receptors (M1, M3, M5)
Bencycloquidium Bromide Nasal Spray	Bencycloquidium Bromide Nasal Spray	Yingu Pharmaceutical Co., Ltd	marketed	Anticholinergic agent	Muscarinic acetylcholine receptor (M3)
Oxybutynin ER	Oxybutynin ER	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Anticholinergic agent	Muscarinic acetylcholine receptors (M3)
Transderm Scop®	Transderm Scop®	University of Iowa	marketed	Anticholinergic agent	Muscarinic acetylcholine receptor (non-selective antagonist)
ACs	ACs	GlaxoSmithKline	marketed	Anticholinergic agent	Muscarinic acetylcholine receptors (non-selective or subtype-specific)
Solifenacin plus Tamsulosin	Solifenacin plus Tamsulosin	Soonchunhyang University Hospital	marketed	Anticholinergic agent + alpha-1A adrenergic antagonist combination	M3 muscarinic receptor; alpha-1A adrenergic receptor
Oxybutynin chloride, extended-release	Oxybutynin chloride, extended-release	US Department of Veterans Affairs	marketed	Anticholinergic agent	M3 muscarinic acetylcholine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic agent class)

1. Repurposed Therapeutics, Inc. · 2 drugs in this class
2. University of Iowa · 2 drugs in this class
3. Alza Corporation, DE, USA · 2 drugs in this class
4. Janssen-Cilag Ltd.,Thailand · 1 drug in this class
5. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
6. Rutgers, The State University of New Jersey · 1 drug in this class
7. Stony Brook University · 1 drug in this class
8. Toronto Rehabilitation Institute · 1 drug in this class
9. US Department of Veterans Affairs · 1 drug in this class
10. University of California, Davis · 1 drug in this class